Supernus Pharma rises as FDA approves ADHD treatment for adults

Supernus Pharmaceuticals

02/05/2022 16:03

** Biopharmaceutical company's shares  SUPN.O  rise 4.6% to
$29.19
    ** Co says U.S. FDA has approved expanded use of its
attention deficit hyperactivity disorder (ADHD) treatment,
Qelbree, in adult patients aged 18 and older  urn:newsml:reuters.com:*:nPn6zlWQJa
    ** Qelbree was approved for treatment of ADHD in patients
aged between 6 and 17 years last year  urn:newsml:reuters.com:*:nL4N2LY112
    ** ADHD is a chronic condition with symptoms including
hyperactivity and impulsive behaviour; it affects an estimated
10 mln adults in the U.S.

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))